Pediatric Anaphylaxis Observation and Epinephrine Timing Study

Study Overview and Citation

• Journal Reference: Dribin TE, et al. Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. Lancet Child Adolesc Health. 2025;9(7):484-496.

• The Bottom Line: A observation window of $2$ hours following the treatment of anaphylaxis with epinephrine is almost always sufficient for patient safety, particularly in cases involving low-risk reactions.

Primary Objective

• The study sought to determine the specific rate and timing of the administration of a second (repeat) dose of epinephrine for pediatric patients in the emergency department (ED) setting.

• It specifically tracked children who had already received an initial dose of epinephrine (either prior to arrival or within the ED) to understand when subsequent doses become necessary during the observation period.

Methodology and Study Population

• Study Design: This was a multicenter retrospective cohort study.

• Data Source: Electronic Medical Record (EMR) records were analyzed from $30$ different emergency rooms.

• Study Duration: The review spanned a period of $3$ years.

• Inclusion Criteria:

  • Age Range: Infants and children aged $6$ months to adolescents aged $17$ years.

  • Clinical Condition: Patients treated for an acute allergic reaction/anaphylaxis.

  • Treatment Requirement: Inclusion required the patient to have received at least one dose of epinephrine either before presenting to the emergency room or while in the emergency room.

• Total Patient Volume: The study reviewed a total of $5641$ patients who met all inclusion criteria.

Results and Statistical Findings

• The study quantified the percentage of patients requiring a repeat dose of epinephrine based on specific time thresholds following the initial dose:

  • Repeat dose > $2$ hours post-initial dose: $4.7\%$ of patients.

  • Repeat dose > $4$ hours post-initial dose: $1.9\%$ of patients.

  • Repeat dose > $6$ hours post-initial dose: $1.1\%$ of patients.

• These findings suggest that the vast majority of patients requiring medical intervention do so within the first $120$ minutes of observation.

Risk Factors for Repeat Epinephrine Administration

• The study identified specific clinical factors associated with a higher likelihood of needing a second dose of epinephrine, quantified by Odds Ratios ($OR$):

  • Pre-Emergency Room Epinephrine Use: Patients who received their first dose before reaching the hospital had the highest odds of needing a subsequent dose ($OR = 4.58$).

  • Severe Cardiovascular Reactions: Patients presenting with severe cardiovascular symptoms had significantly increased odds ($OR = 3.18$).

  • Severe Respiratory Reactions: Patients with severe respiratory involvement also showed increased odds, though to a lesser degree than cardiovascular or pre-hospital administration ($OR = 1.47$).

Clinical Implications and Editor's Commentary

• Observation Windows: There is very little clinical benefit to observing most patients for longer than $2$ hours in the ED following anaphylaxis treatment.

• Personalized Care Decisions: Clinicians and families can use this data to tailor observation timelines based on individual patient factors. High-risk considerations include:

  • A history of previous severe anaphylaxis.

  • Current use of an asthma controller medication.

• Safety Considerations: Decisions regarding discharge after the $2$-hour window should also weigh the patient's logistical ability to return for emergency care or their proficiency in re-dosing epinephrine at home should a biphasic or recurrent reaction occur.